Concepedia

Population Pharmacokinetic Analysis of Abiraterone in Chemotherapy-Naïve and Docetaxel-Treated Patients with Metastatic Castration-Resistant Prostate Cancer

Kim Stuyckens, Fred Saad, Xu Steven Xu, Charles J. Ryan, Matthew R. Smith, Thomas W. Griffin, Margaret K. Yu, An Vermeulen, Partha Nandy, Italo Poggesi

Clinical Pharmacokinetics · 2014 · 54 citations · 26 references

DOI

Concepts

References

26

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Charles J. Ryan, Matthew R. Smith, Johann S. de Bono et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

, , +17

Some suggestions for measuring predictive performance

Lewis B. Sheiner, Stuart L. Beal · Journal of Pharmacokinetics and Biopharmaceutics · 1981 · 1.6K citations

, , +8

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Karim Fizazi, Howard I. Scher, Arturo Molina et al. · The Lancet Oncology · 2012 · 1.4K citations

, , +17

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

Gerhardt Attard, Alison Reid, Timothy A. Yap et al. · Journal of Clinical Oncology · 2008 · 896 citations · Full text

, , +17

Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays

C.T. Viswanathan, Surendra K. Bansal, Brian Booth et al. · Pharmaceutical Research · 2007 · 815 citations

, , +16